<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007860.ref030">
 <label>30</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Mimura</surname>
   <given-names>Y</given-names>
  </name>, 
  <name>
   <surname>Katoh</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Saldova</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>O'Flaherty</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Izumi</surname>
   <given-names>T</given-names>
  </name>, 
  <name>
   <surname>Mimura-Kimura</surname>
   <given-names>Y</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy</article-title>. 
  <source>Protein &amp; cell</source>. 
  <year>2018</year>;
  <volume>9</volume>(
  <issue>1</issue>):
  <fpage>47</fpage>â€“
  <lpage>62</lpage>. 
  <pub-id pub-id-type="doi">10.1007/s13238-017-0433-3</pub-id>
  <?supplied-pmid 28597152?>
  <pub-id pub-id-type="pmid">28597152</pub-id>
 </mixed-citation>
</ref>
